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Background:Thepurpose of this study is to assess the combined exercise programs (12weeks’
physical exercise training, resistance and aerobic) and 6weeks’ detraining on the correlation
of metabolic syndrome (MS) markers and plasma adiponectin level in two groups.
Methods: Participants were divided into two groups [physical exercise training group (EG,
n=8) and control group (CG, n=7)]. The EG performed a 12-week training program (aerobic
and resistance training twice/wk, more than 40min/d). After 12 weeks’ exercise training and
6 weeks’ detraining, we also evaluated MS markers and plasma adiponectin at three time
periods (baseline, EBP; 12 weeks’ exercise program, 12 EP; 12 weeks’ and 6 weeks’ detraining,
12+6 EDP) in overweight and obese children.
Results: Compared with the CG, After the 12 weeks’ exercise treatment, weight, body mass
index (BMI), waist girth, percent body fat, lean body mass (LBM), percentage lean body,
systolic blood pressure, and insulin and homeostatic model assessment (HOMA) indices
were lowered in the EG, and plasma adiponectin levels were not altered in the EG. After 6
weeks’ detraining, insulin, insulin resistance, and plasma adiponectin levels were signiﬁ-
cantly increased in the EG. In the adiponectin level, there were positive correlations with
LBM and percent lean body and negative correlations with percent body fat, insulin, and
insulin resistance after 12 weeks’ physical exercise intervention and 6 weeks’ detraining.
Conclusion: These ﬁndings suggest that combined physical training is a useful tool in themanagement of MS markers in the training periods. Moreover, there was an additive effect
even after the 6-weeks detraining period.© 2013 Korea Institute o
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1. Introduction
Metabolic syndrome (MS) is a combined medical disorder that
affects the risk of developing type 2 diabetes mellitus (T2DM)
and cardiovascular diseases. It has been revealed that the esti-
mated prevalence is up to 25% of the US population.1
It is well known that MS is the clustering of dyslipidemia,
impaired insulin sensitivity, hypertension, obesity, T2DM, and
cardiovascular disease.2,3
It is well reported that regular physical exercise can
enhance MS markers and decrease cardiovascular diseases
and premature mortality.4 Also, various kinds of physical
activity programs based either on aerobic exercise, resistance
training, or a combined type of physical activity may promote
insulin sensitivity and weaken or suppress MS in children.
Several sets of criteria are in use for MS diagnosis: athero-
genic dyslipidemia, hypertension, elevated blood glucose,
obesity, insulin sensitivity, and T2DM.5 Adiponectin level is
also an important factor in estimating MS.
Adiponectin is known as an endogeneous insulin sen-
sitizer, which plays an important role as a modulator of
peroxisome proliferator activated receptor gamma action. It
has a reverse correlation with obesity and serum levels.6
It has been found that plasma adiponectin plays a key role
in regulating obesity, carbohydrate metabolism, and insulin
resistance,7,8 and it has been revealed that it decreases in
obese individuals and T2DM patients.9–11
Plasma adiponectin also increases insulin sensitivity
through enhancing fatty acid oxidation in skeletal muscle,
liver, and blood vessels.12,13 It has also been reported that
exercise training improves insulin sensitivity activating 5′
adenosine monophosphate-activated protein kinase (AMPK)
in skeletal muscle.14 Most of the previous researches have
revealed the negative relationship between insulin level and
plasma adiponectin level.11,15 Several papers revealed that the
adiponectin level increased meaningfully with the enhance-
ment of insulin resistance.15–21 However, some research
papers report that there is no connection between insulin
sensitivity and adiponectin level. Other studies reported no
change in plasma adiponectin level or even decreased rather
than increased levels after exercise intervention, despite the
enhanced level of insulin.18,19,22–24
Therefore, we can conclude that regular exercise train-
ing enhances MS with insulin resistance. Generally, there are
two possible mechanisms: the ﬁrst is adiponectin dependent,
and the second is adiponectin independent. Physical exer-
cise increases insulin sensitivity throughAMP kinase pathway
activation. It has recently been revealed that adiponectin also
improves muscular insulin sensitivity through the same pro-
cess. However, it is generally understood that several weeks
of exercise training increases adiponectin levels with insulin
sensitivity.
Further research is needed on the correlation between
plasma exercise training and adiponectin level. However, lit-
tle research has been carried out on the mechanisms and
correlation of exercise and adiponectin responses. Therefore,
in our study, we analyzed the relationships between plasma
adiponectin level and insulin sensitivity following 12 weeks’
exercise training and 6 weeks’ detraining.Integr Med Res ( 2 0 1 3 ) 145–150
2. Methods
2.1. Participants
Fifteen young overweight [known body mass index (BMI) per-
centile 85–94] and obese children (known BMI percentile > 95)
participated in the present study.25 The criteria for partic-
ipating in the current research included no experience of
cardiovascular disease,1,2 no use of medical substances,3 no
experiences of regular exercise training, and no smoking.
The 15 participants were unintentionally divided into two
groups [exercise training group (EG, n=8) and control group
(CG, n=7)] and three periods (baseline, EBP; 12 weeks’ exercise
program, 12 EP; 12 weeks’ and 6 weeks’ detraining, 12+6 EDP).
Informed consent was taken from the participants and
their parents after they were given a detailed explanation
about the study’s purpose and methods. This experiment was
approved by the Dong-Eui University and Pusan National Uni-
versity Ethics Committee.
2.2. Exercise protocol
The exercise programwas chosen froma randomized and con-
trolled clinical trial designed to study the combined effects of
physical exercise programs. The combined exercise training
program was composed of walking exercises and band exer-
cises, which were supervised by many exercise specialists.
Walking exercise was practiced twice a week at 55–64%
heart ratemax (HRmax) and 65–75%HRmax, based on the Kar-
vonen formula, for Weeks 1–6 and Weeks 7–12, respectively, as
an aerobic exercise (30min for 1–6 wk and 35min for 7–12 wk).
Rubber band exercises were practiced twice a week as
resistance training (50min/d). Rubber band exercises were
composed of nine exercises: squat, sit-up, seated row, knee
extension, knee curl, seated leg press, overhead press, elbow
curl, and bench press.
Each movement was performed at 70% of the maximal sin-
gle repetition. Resistance exercise was increased slowly when
the individuals could perform 20 repetitions without recess.
The participants increased the thickness of the rubber to
increase the exercise intensity. This was accomplished by uti-
lizing the different thicknesses of the band products.
All physiological variables were assessed at three periods
(EBP, 12 EP, and 12+6 EDP).
2.3. Baseline, 12 weeks’ exercise training, and 6
weeks’ detraining measurements
Bodyweight andheightwere gaugedusing adigital scalewhile
wearing pants but no shoes. Waist girth was also gauged using
a tapeline between the iliac crest at the bottom of the rip.
Blood pressure was measured using an automatic device
(DINMAP; Critikon, Inc., Lockbourne, OH, USA) and measured
twice on arms after a 10-minute rest on the bench with an
appropriate-sized cuff, and the mean value was used in the
result.
Body composition was determined using dual-energy
X-ray absorptiometry (DEXA, Lunar Prodigy; GE Medical
Systems, Waukesha, WI, USA), a sensitive test for quantifying
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lterations in fat and lean mass in vivo26 and for evaluating
egional fat distribution.27
For all individuals, blood samples were taken in the
orning from the antecubital vein following a 12-hour
vernight fast; fasting glucose, serum insulin, total choles-
erol, triglyceride, and adiponectin levels were determined.
lood samples were taken at baseline, 12 weeks’ training, and
weeks’ detraining.
Blood samples were drawn into chilled tubes containing
a2EDTA (1 g/L) and aprotinin (500 U/mL). Extracted plasma
as immediately isolated by centrifugation at 4 ◦C and kept
t –80 ◦C until analyzed. Glucose levels were also gauged
nzymatically (glucose oxidase) within 4hours of collection,
tilizing a Synchron LX 20 (Beckman Coulter Inc., Fullerton,
A, USA). Insulin levels were assayed by radioimmunoas-
ay (RIA, Coat-A-Count; Diagnostic Products Corporation, Los
ngeles, CA, USA), using antibody-coated tubes. The mean
oefﬁcients of variation (CVs) were 4.2% and 6.3% separately.
he homeostatic model assessment (HOMA) index was also
easured by using the following formula: fasting plasma glu-
ose (mmol/L)× fasting plasma insulin (mU/L)/22.5.28
Plasma adiponectin was measured using an enzyme-
inked immunosorbent assay (ELISA) kit (B-Bridge interna-
ional, Inc., Sunnyvale, CA, USA). The mean CVs were 4.1%
nd 7.4% for adiponectin. High density lipoprotein cholesterol
HDL) and triglyceride levels were calculated utilizing a Syn-
hron LX20 analyzer (Beckman Coulter, Fullerton, CA, USA)..4. Data analysis
n this study, we analyzed the relationships between plasma
diponectin level and insulin sensitivity following 12 weeks’
Table 1 – The changes in metabolic syndrome (MS) parameters
detraining.
EG (n=8)
Pre
(0 week)
Post
(12 weeks)
Detraining
(6 weeks)
Weight (kg) 54.44±8.2 50.75±7.31 52.10±8.16
BMI (kg/m2) 24.68±2.68 22.41±2.22 22.90±2.42
Waist girth (cm) 83.45±3.75 82.40±3.14 82.94±2.87
BFM (kg) 18.83±3.62 14.92±3.24 15.82±3.56
PBF (%) 34.49±3.04 29.32±4.25 30.20±4.16
LBM (kg) 34.01±5.08 34.23±5.25 34.64±5.41
PLB (%) 62.59±2.91 67.53±4.12 66.66±4.01
SBP (mmHg) 100.38±8.35 98.36±6.01 101.75±6.14
DBP (mmHg) 60.88±7.20 75.63±8.62 71.25±8.41
TG (mg/dL) 110.63±72.56 33.00±12.07 74.13±32.29
HDL-C (mg/dL) 44.00±12.02 56.37±11.88 53.75±7.59
Glucose (mg/dL) 70.63±8.26 90.38±7.01 91.13±4.38
Insulin (IU/mL) 15.68±12.64 5.14±1.01 6.86±3.90
HOMA-IR index 2.65±2.04 0.90±0.22 1.21±0.71
Adiponectin (g/mL) 12.11±4.95 12.16±4.10 17.17±5.91
* Signiﬁcant difference of interaction effect between group and time in tw
baseline, † p<0.05, ‡ p<0.001.
§ Signiﬁcant difference of interaction effect between group and time in two
|| p<0.05, ¶ p<0.01, ** p<0.001.
ANOVA, analysis of variance; BMI, body mass index; BFM, body fat mass;
HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostatic model
of body fat; PLB, percentage of lean body; SBP, systolic blood pressure; TG,147
physical exercise training and 6 weeks’ detraining. The results
were expressed as mean± standard deviation (SD).
The Kolmogorov-Smirnov test (K-S test) was performed
in advance to conﬁrm normal distribution of each variable.
We analyzed the data utilizing two-way repeated measures
of analysis of variance (ANOVA) in the comparison study to
analyze the effects of groups and periods. The correlation
between plasma adiponectin and other variables was esti-
mated by using Pearson’s correlation coefﬁcients. A p<0.05
was considered signiﬁcant.
All data analyses were performed using SPSS version 15.0
statistics program (SPSS Inc., Chicago, IL, USA).
3. Results
Themeasurements ofMSmarkers andadiponectin levels after
12 weeks’ exercise intervention and 6 weeks’ detraining are
shown in Table 1.
In theweight (p<0.001), BMI (p<0.001), waist girth (p<0.05),
fat mass (p<0.001), % fat (p<0.001), lean body mass (LBM,
p<0.05), % LBM (p<0.001), systolic blood pressure (SBP,
p<0.05), insulin (p<0.05), and HOMA-IR (p<0.05) levels, there
were signiﬁcant differences between EG and CG following 12
weeks’ exercise training. However, there were no signiﬁcant
differences between time and group in DBP, TG, HDL-C, blood
glucose, and adiponectin.
After 6 weeks’ detraining, group analyses showed signif-
icant differences in time×group interaction in several MS
markers. They were signiﬁcantly much improved in weight
(p<0.001), BMI (p<0.001), fat mass (p<0.001), % fat (p<0.01),
LBM (p<0.05), % LBM (p<0.01), and adiponectin (p<0.01)
and adiponectin after 12 weeks’ exercise and 6 weeks’
CG (n=7) F* F§
Pre
(0 week)
Post
(12 weeks)
Detraining
(16 weeks)
59.36±5.88 60.83±6.29 61.76±6.35 57.57‡ 36.03**
25.32±1.60 25.45±1.72 25.71±1.68 54.21‡ 31.56**
83.86±2.92 84.29±2.53 84.14±2.72 8.40† 0.85
21.23±2.11 21.35±2.63 21.85±2.69 39.29‡ 25.56**
35.81±2.11 35.11±2.45 35.39±2.47 26.09‡ 16.84¶
36.42±4.17 37.70±4.28 38.09±4.09 4.75† 5.43||
61.27±2.06 61.94±2.39 61.64±2.24 22.99‡ 15.22¶
115.00±101.29 107.71±10.01 109.14±9.84 6.41† 3.69
64.71±5.22 86.29±8.30 83.71±8.58 .98 2.87
102.71±74.61 74.14±66.88 87.14±66.44 3.40 0.57
41.57±6.95 50.57±12.58 52.86±12.94 0.30 0.60
73.00±7.94 94.43±7.14 95.43±5.32 0.12 0.19
12.44±6.13 13.87±6.86 14.43±14.20 5.58† 2.53
2.22±1.05 2.54±1.37 2.71±2.94 5.78† 2.37
14.06±5.61 14.42±4.27 13.6±4.85 0.10 14.71¶
o-way repeated ANOVA after 12 weeks’ exercise treatment based on
-way repeated ANOVA after 18 weeks’ detraining based on baseline,
CG, control group; DBP, diastolic blood pressure; EG, exercise group;
assessment-insulin resistance; LBM, lean body mass; PBF, percentage
triglyceride.
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Table 2 – The correlations between plasma adiponectin concentration and metabolic syndrome (MS) markers.
0–12 weeks 0–18 weeks 12–18 weeks
EG (n=8) CG (n=7) EG (n=8) CG (n=7) EG (n=8) CG (n=7)
Weight (kg) –0.322 –0.105 0.148 –0.433 0.179 –0.198
 BMI (kg/m2) –0.196 –0.023 0.099 –0.362 0.218 –0.394
Waist circumference (cm) 0.189 0.035 0.154 –0.398 0.262 0.110
 SBP (mmHg) 0.560 0.048 –0.074 –0.012 –0.167 –0.159
 DBP (mmHg) 0.376 0.067 –0.142 –0.614 0.335 0.745
 BFM (kg) –0.415 –0.595 0.128 –0.561 –0.489 –0.323
 PBF (%) –0.330 –0.732 0.252 –0.462 –0.717* –0.327
 LBM (kg) 0.157 0.534 0.005 0.088 0.792* 0.167
 Percentage of lean body (%) 0.315 0.733 –0.270 0.476 0.732* 0.315
 TG (mg/dL) 0.591 –0.264 0.628 0.013 –0.531 –0.594
 HDL-C (mg/dL) –0.064 –0.247 –0.252 –0.406 0.281 –0.117
 Blood glucose (mg/dL) –0.376 –0.528 –0.183 –0.717 –0.083 –0.710
 Insulin (IU/mL) –0.075 0.313 0.295 0.763 –0.750* 0.425
 HOMA-IR index –0.109 0.298 0.319 0.744 –0.728* 0.432
, baseline data minus data at 12 weeks and baseline data minus data at detraining (18 weeks) and 12 weeks data minus data at detraining (18
weeks).
* p<0.05.
EG, ex
ss; PBBFM, body fat mass; CG, control group; DBP, diastolic blood pressure;
homeostaticmodel assessment-insulin resistance; LBM, leanbodyma
compared to CG. However, there were no signiﬁcant differ-
ences in time×group in waist girth, SBP, DBP, TG, HDL-C,
blood glucose, insulin, and HOMA-IR.
The correlations between adiponectin and MS markers
are shown in Table 2. There was no correlation between
adiponectin and MS markers after 12 weeks’ physical exer-
cise training and 6 weeks’ detraining (12 weeks’ exercise
training+6 weeks’ detraining). However, there was a positive
correlation in the 6-week detraining period (Fig. 1).
There were positive correlations between adiponectin and
LBM (r=0.792, p<0.05) and percent of lean body (r= –0.732,
p<0.05); there were negative correlations with percent body
fat (r= –0.717, p<0.05), insulin (r= –0.750, p<0.05), and insulin
resistance (r= –0.728, p<0.05) after 6 weeks’ detraining.
Fig. 1 – Changes in adiponectin.
* Signiﬁcant difference of interaction effect between groups
and times in two-way repeated ANOVA after 12 weeks’
exercise training and 6 weeks’ detraining based on
baseline, p<0.01.
ANOVA, analysis of variance; CG, control group; EG,
exercise group.ercise group; HDL-C, high density lipoprotein cholesterol; HOMA-IR,
F, percentage of body fat; SBP, systolic bloodpressure; TG, triglyceride.
4. Discussion
Adiponectin is an adipose-speciﬁc secretory protein that
shows great potential as a novel mediator, having an anti-
atherogenic properties. It enhances the peripheral insulin
sensitivity and affects beta-cell function.29,30
It is well published that adiponectin is signiﬁcantly
decreased in rodents,31 monkeys,32 and human patients
with obesity and T2DM patients,10,11,33 and also in patients
with coronary artery disease.34 There is a reverse correlation
between adiponectin level and obesity-related factors such
as fasting plasma insulin, abnormal oral glucose tolerance,
fat distribution, and percentage body fat, and a positive cor-
relation with glucose disposal during a euglycemic insulin
clamp.10,11,31,33
It is generally understood that plasma adiponectin levels
increased after weight loss caused by dietary therapy. Also,
levels were reduced in patients with T2DM,11 obesity,9,35 and
coronary artery disease.36
According to some research papers, it is reported that
plasma adiponectin level is increased after ﬂexibility exercise
and aerobic exercise intervention.19,37
On the contrary, Boudou et al22 reported that plasma
adiponectin level was not changed despite reduced abdom-
inal fat and increased insulin sensitivity without a signiﬁcant
alteration in body weight after 8 weeks’ exercise intervention
in 16 middle-aged men with T2DM.
Although regular exercise training is used as a useful tool to
ameliorate obesity, insulin resistance, andweight control, only
a few research studies have been executed on the relationship
between adiponectin level and physical exercise training.38
In these experiments, adiponectin levels increased or
remained constant following exercise training. Therefore, we
need to further investigate themechanismbehind the correla-
tion between plasma adiponectin level and physical exercise
training.
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Moreover, in this paper, we evaluated the adiponectin
nd metabolic markers in two periods: 12 weeks’ exercise
raining and 6 weeks’ detraining. The main ﬁnding of this
nvestigation was that 12 weeks’ combined training improved
aist circumference, body weight, body fat, BMI, percent body
at, insulin, and HOMA-IR without adiponectin. A previous
tudy showed that exercise training improved MS markers for
nsulin sensitivity.39
Adiponectin levels did not vary after 12 weeks of physical
raining in the present research. However, insulin sensitivity
mproved in obese children. Similar results have been revealed
n other papers.40 The beneﬁcial effects of 6 weeks’ detraining
n MS markers and adiponectin were observed. After 6 weeks’
etraining, there was an additive effect of weight, BMI, body
at, and percent body fat.
An amusing ﬁnding of the present investigation is that
diponectin was much improved following 6 weeks’ detrain-
ng not following the 12 weeks’ exercise training. These
esults are also in accordance with those of previous exper-
ments on other overweight and obese children that exercise
raining induced enhancements in body fat, waist circum-
erence, body weight, BMI, and insulin sensitivity without
diponectin.41
Detraining has been redeﬁned as the complete or par-
ial loss of training-induced psychological, anatomical, and
hysiological performance adaptation, as an outcomeof train-
ng reduction or training cessation.42 This is consistent with
nother researchpaperwhere detraining increased the level of
diponectin through increased insulin sensitivity and glucose
ransporters.43 In another study, body fat mass was signiﬁ-
antly improved after 8 weeks of physical exercise training in
oung obese men.
BMI, weight, percent body fat, and body fat mass were
eported to be signiﬁcantly improved after 5 months of
ombined exercise (aerobic exercise and resistance exercise)
raining, whereas there was no alteration in insulin sensi-
ivity and adiponectin in both groups.44 Generally, plasma
diponectin levels have been shown to reduce simultaneously
ith the development of insulin resistance.32
According to this study, after 12 weeks’ combined physical
xercise intervention, some MS markers and insulin resis-
ance were improved signiﬁcantly but plasma adiponectin
evels were not altered statistically. However, after 6 weeks’
etraining, plasma adiponectin levels signiﬁcantly increased.
e ﬁnd that adiponectin level is altered after 12 weeks’
xercise and 6 weeks’ detraining. With such results showing
imilarity in the negative relationship between insulin resis-
ance and adiponectin (and its process of metabolism), it is
lear that exercise enhances muscle and blood functions and
lso improves insulin sensitivity through activation of AMPK
n skeletal muscle.22
After 6 weeks’ detraining, there was a positive corre-
ation between lean body mass and percent lean body
ith adiponectin, whereas there was a negative correlation
etweenadiponectin andpercent body fat, insulin, and insulin
esistance. With such results, we ﬁnd that decreased insulin
romotes transportation of glucose, and then it inﬂuences
he increase in plasma adiponectin levels.45 Also, plasma
diponectin level has been correlated with percent body fat
nd BMI.9,46149
These results suggest that combined physical training is
not only an effective tool in the management of syndrome
markers in the training periods but also these changes were
retainedor evenaccumulated after 6weeks’ detraining. There-
fore, we can conclude that there is an enhanced adiponectin
effect in the detraining period.
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